EMERGENT BIOSOLUTIONS INC. Proceeds from Sale of Other Assets
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Sale of Other Assets of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfOtherAssets1 · last filed 2015-03-09
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of other assets for fiscal 2014 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of other assets for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of other assets for fiscal 2012 was $11.77M.
- EMERGENT BIOSOLUTIONS INC. proceeds from sale of other assets for fiscal 2011 was $0.00.
| Period end | Proceeds from Sale of Other Assets 12 month |
|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-09 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-09 |
| 2012-12-31 | $11.77M 10-K · filed 2015-03-09 |
| 2011-12-31 | $0.00 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |